Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
1(25%)
Results Posted
0%(0 trials)

Phase Distribution

Ph not_applicable
2
50%

Phase Distribution

0

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution2 total trials
N/ANon-phased studies
2(100.0%)

Highest Phase Reached

Unknown

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(3)

Detailed Status

Completed3
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
N/A

Trials by Phase

N/A2 (100.0%)

Trials by Status

active_not_recruiting125%
completed375%

Recent Activity

1 active trials
Showing 4 of 4
active_not_recruitingnot_applicable

Surveillance of High-grade Non-muscle Invasive Bladder Tumours Using the Xpert Bladder Cancer Monitor

NCT04100733
completed

A Multi-National Study In Bladder Cancer Patients to Detect Recurrences After TURB (Trans-urethral Resection of the Bladder) Earlier With the Xpert Bladder Cancer Monitor Assay (ANTICIPATE X)

NCT03664258
completed

Clinical Evaluation of a Test for Monitoring the Recurrence of Bladder Cancer

NCT03125460
completednot_applicable

Xpert Bladder Cancer Monitor; Prospective, Single, Tertiary-care Center Implementation Study

NCT03715660

Clinical Trials (4)

Showing 4 of 4 trials
NCT04100733Not Applicable

Surveillance of High-grade Non-muscle Invasive Bladder Tumours Using the Xpert Bladder Cancer Monitor

Active Not Recruiting
NCT03664258

A Multi-National Study In Bladder Cancer Patients to Detect Recurrences After TURB (Trans-urethral Resection of the Bladder) Earlier With the Xpert Bladder Cancer Monitor Assay (ANTICIPATE X)

Completed
NCT03125460

Clinical Evaluation of a Test for Monitoring the Recurrence of Bladder Cancer

Completed
NCT03715660Not Applicable

Xpert Bladder Cancer Monitor; Prospective, Single, Tertiary-care Center Implementation Study

Completed

All 4 trials loaded

Drug Details

Intervention Type
DEVICE
Total Trials
4